Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Journal of Medical Economics Année : 2020

Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France

Résumé

Background: Lymphomas are costly diseases that suffer from a lack of detailed economic information, notably in a real-world setting. Decision-makers are increasing the search for Real-World Evidence (RWE) to assess the impact, in real-life, of healthcare management and to support their public decisions. Thus, we aimed to assess the real-world net costs of the active treatment phases of adult Hodgkin Lymphoma (HL), Follicular Lymphoma (FL) and Diffuse Large B Cell Lymphoma (DLBCL). Methods: We performed a retrospective cohort study using population-based data from a national representative sample of the French population covered by the health insurance system. Cost analysis was performed from the French health insurance perspective and took into account direct and sick leave compensation costs (e2,018). Healthcare costs were studied over the active treatment phase. We used multivariate modeling to adjust cost differences between lymphoma subtypes. Results: Analyses were performed on 224 lymphoma patients and 896 controls. The mean additional monthly costs due to HL, FL and DLBCL patients were respectively e5,188, e3,242 and e7,659 for the active treatment phase. The main additional cost driver was principally inpatient stay (hospitalization costs and costly cancer-related drugs), followed by outpatient medication and productivity loss. When adjusted, DLBCL remains significantly the most costly lymphoma subtype. Conclusion: This study provides an accurate assessment of the main lymphoma subtypes related cost with high magnitude of details in a real-world setting. We underline where potential cost saving could be realized via the use of biosimilar medication, and where lymphoma management could be improved with the early management of adverse events.
Fichier principal
Vignette du fichier
IJME_A_1702990.pdf (930.49 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-02533775 , version 1 (09-04-2020)

Identifiants

Citer

Michael Mounie, Nadège Costa, Cécile Conte, Dominique Petiot, Didier Fabre, et al.. Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France. Journal of Medical Economics, 2020, 23 (3), pp.235-242. ⟨10.1080/13696998.2019.1702990⟩. ⟨hal-02533775⟩
107 Consultations
243 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More